Subsidiary obtains drug registration certificate for injectable multivitamins (12)
August 10, 2026
Source: drugdu
32
Wei Xinkang(603676.SH) announced that its wholly-owned subsidiary, Baiyi Pharmaceutical, received approval from the National Medical Products Administration for injectable multivitamins .(12) Drug Registration Certificate. This drug is a Class 4 chemical drug and is considered to have passed the consistency evaluation. In 2025, the sales of this drug in domestic public medical institutions reached RMB 1.601 billion, and the cumulative R&D investment as of the end of July 2026 was RMB 11.3139 million.
https://finance.eastmoney.com/a/202608073835199693.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap August 10, 2026
- Vonoprazan Fumarate Tablets Receive Drug Registration Certificate August 10, 2026
- Lenvatinib Mesylate Capsules Receive Drug Registration Certificate August 10, 2026
- Loxoprofen Sodium Patch Receives Drug Registration Certificate August 10, 2026
- its stock price has shrunk by 90% from its issue price, and although it has finally received approval for its first product, the market landscape has already changed. August 4, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
